Lucknow, India : Chandan Healthcare Limited (NSE – CHANDAN), – Chandan Healthcare Limited, one of the leading players in North India’s Diagnostics sector, has announced its Unaudited Financial Results for Q3 FY26 & 9M FY26.

Consolidated Key Financial Highlights:

Key Financial Highlights Q3 FY26

  • Total Income of ₹ 65.77 Cr, YoY growth of 19.99%
  • EBITDA of ₹ 12.61 Cr, YoY growth of 39.08%
  • EBITDA Margin of 19.17%, YoY growth of 263 BPS
  • Net Profit of ₹ 4.54 Cr, YoY growth of 7.97%
  • Net Profit Margin of of 6.90%

Key Financial Highlights 9M FY26

  • Total Income of ₹ 203.27 Cr, YoY growth of 21%
  • EBITDA of ₹ 42.59 Cr, YoY growth of 38.58%
  • EBITDA Margin of 20.95%, YoY growth of 266 BPS
  • Net Profit of ₹ 20.14 Cr, YoY growth of 24.71%
  • Net Profit Margin of of 9.91%, YoY growth of 29 BPS

Commenting on the financial performance, Mr. Amar Singh, Promoter and Managing Director of Chandan Healthcare Limited, said, “We delivered a steady performance in Q3 FY26 with Total Income of ₹65.77 Cr and EBITDA of ₹12.61 Cr, reflecting healthy operating momentum and improved efficiencies. Our continued focus on network expansion, value-added testing, and operational discipline supported stable margins and consistent growth during the quarter.

During the quarter, we entered into an exclusive five-year partnership with Jeena Sikho Lifecare to provide comprehensive diagnostic services across its existing and upcoming hospitals and centres. This strategic collaboration is expected to generate meaningful recurring revenues at healthy margins over the coming years. We have already commenced the operational rollout under this partnership by setting up diagnostic facilities, and this will progressively ramp up going forward. In addition, we secured a key B2G contract during the quarter, adding business stability and ensuring steady test volumes.

We are expanding rapidly and targeting the development of around 100 labs across 17 states along with over 1,000 franchise collection points over the next three years. With a planned investment of approximately ₹100 Cr to support expansion and advanced testing capabilities including molecular diagnostics, we remain confident of strengthening our pan-India presence and driving sustainable long-term growth.”